<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Evaluate Human Specific CD137 Antibodies

Despite the huge clinical success of PD-1/PD-L1 checkpoint inhibitors in multiple tumor types, overall response rate to these agents is still low.